Skip to main content
. 2022 Jul 1;7(4):100517. doi: 10.1016/j.esmoop.2022.100517

Figure 1.

Figure 1

Change from baseline for EORTC QLQ-C30 scores at week 12 and week 18. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; GHS, global health status; ICC, investigator-chosen chemotherapy; LS, least square; n, patients with baseline and at least one post-baseline measurement; QoL, quality of life; TIS, tislelizumab.